{"entity":{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","aka":[],"tldr":"The PD-1 antibody dostarlimab shrank tumours in about four in ten women with mismatch repair-deficient endometrial cancer that had progressed after platinum chemotherapy, with most responses still ongoing after a year.","summary":"Interim analysis of the phase 1 GARNET trial's cohort of 104 patients with mismatch repair-deficient recurrent or advanced endometrial cancer treated with dostarlimab after platinum-based therapy.\n\nObjective response was 42.3 percent with complete response in 12.7 percent, and 93 percent of responses were ongoing at data cut-off; immune-related toxicity was manageable.","asOf":"2026-09-17","links":[{"label":"JAMA Oncol 2020","url":"https://doi.org/10.1001/jamaoncol.2020.4515"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33001143/"}],"tags":[],"related":[],"cancers":["endometrial-mmr-deficient"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["garnet"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama-oncology"],"dependsOn":[],"notes":[],"journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2020.4515","pmid":"33001143","authors":"Oaknin A, Tinker AV, Gilbert L, et al.","paperType":"observational","findings":["Objective response 42.3 percent; complete response 12.7 percent.","Median duration of response not reached; 93 percent of responses ongoing."],"whatItMeans":"Dostarlimab was approved for previously treated mismatch repair-deficient endometrial cancer on these data, before moving into first-line combination in RUBY.","caveats":["Single-arm, interim data.","Response in mismatch repair-proficient disease was much lower (about 13 percent) in a parallel cohort."],"changedPractice":true,"participants":104},"route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/","neighbours":{"cancer":[{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"trial":[{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/"}],"journal":[{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/"}]}}